Prof. Dr. A.V. SRINIVASAN
M.D., D.M., Ph.D (Neuro)DSC(HON), F.A.A.N., F.I.A.N,
    FORMER -Professor in Neurology and HEAD
        Institute of Neurology, MMC & GGH
                  17-06-2011
Male Brain vs. Female Brain
Different in external anatomical and primary and
 secondary sexual differences
There are also differences in the way male and female
 brains process language, information, emotion,
 cognition, etc (3).
Differences
Male Brain                  Female Brain
Better in Mathematical     Better in human relations.
 calculations, etc.         Higher than males in
Higher than females in       empathy, verbal skills, social
 independence, dominance,     skills, and security seeking
 spatial and mathematical     (3).
 skills, rank-related
 aggression, and other
 characteristics (3).
Physiological Differences
Brain region in cortex discovered by scientists in
 Johns Hopkins University: inferior-parietal lobule
 (IPL).
  Significantly larger in men than in women.
  This area is bilateral and located just above the parietal
    cortex (above the level of the ears).
Left IPL larger for men, while right IPL larger for
 women.
Women have more grey matter volume than do men
 (3).
Regions other than the Cortex
the volume of a specific nucleus in the
 hypothalamus (third cell group of the interstitial
 nuclei of the anterior hypothalamus) is twice as
 large in heterosexual men than in women and
 homosexual men, thus prompting a heated
 debate whether there is a biological basis for
 homosexuality (3).
Headaches
Common medical              Types:
 problem by any standard       Migrane
Represents most               Tension
 common reason for             Cluster
 referral for Neurologists
 (2).
Migraine
Migraine—disorder of sensory dysmodulation (2).
  Most common of the disabling primary headaches
  Represents 90% of headache complaints
Pathophysiology: inherited problem (2).
 Thus far, 3 genes for familial hemiplegic migraine
   identified
 Each involve dysfuntion of ion channels.
Headaches in Women
Women have headaches more commonly than men.
  Prevalence of migraine: 18% of women and 6% of men.
Estrogen levels are a key factor in increased
 prevalence of migraine in women (1).
Evidence of the Effect of Estrogen
levels on Migraines
Migraine prevalence increases at menarche
Estrogen withdrawal during menstruation is a common
 trigger for migraine
Estrogen administration in oral contraceptives and
 hormone replacement therapies can also trigger
 migraines.
Migraines decrease during the 2nd and 3rd trimesters of
 pregnancy when estrogen levels are high
Migraines are common immediately postpartum, with the
 precipitous drop in estrogen levels
Migraines generally improve with physiological
 menopause (1).
Effects of Estrogen levels (1).
Fluctuations of estrogen levels can result in:
  Changes in prostaglandins and the uterus
  Prolactin release
  Opioid regulation
  Melatonin secretion
  Changes in neurotransmitters
       I.e. Catecholamines, noradrenaline, serotonin, dopamine,
        and endorphins.
Lifetime Prevalence of Headaches
in Women and Men (1).
Type           Women   Men
Any Headache   99%     93%
Migraine       25%     8%
Tension        88%     69%
Important Headache Issues to be
Covered (1).
Menstrual Migraine
Menopause and Migraine
Oral Contraceptive Use in Migraineurs
Headaches during Pregnancy and Postpartum
Menstrual Migraine (1).
Prevalence varies from 4% to 73%
Menstruation is trigger for about 60% of migraineurs.
Symptoms of premenstrual syndrome include:
 depression, anxiety, crying spells, difficulty thinking,
 lethargy, backache, breast tenderness, swelling, and
 nausea.
  Both Migraine and tension-type headaches can be
    associated.
Management of Menstrual
Migraine (1).
Symptomatic treatment same as for other migraines –
 NSAIDs (nonsteroidal antiinflammatory drugs) –
 ergotamine, dihydroergotamine, and triptans.
Premenstrual preventive treatment can be helpful for
 women with frequent migraines or with menstrual
 migraines that are severe and prolonged.
Management of Menstrual
Migraine (1)>
Effective Hormonal treatments
  Transdermal estradiol
  Bromocriptine 2.5mg, three times a day
  Danazol 200mg, two or three times a day
  Tamoxifen 5 to 15mg daily for days 7-14 of the luteal
    cycle.
Hysterectomy is NOT RECOMMENDED for the
 management of menstrual migraine.
Menopause and Migraines (1).
2/3rds of women with prior migraine improve with
 physiological menopause.
Contrastingly, surgical menopause results in the
 worsening of migraine in 2/3rds of cases.
Menopause and Migraines:
Estrogen Replacement Therapy (1).
Effect of hormone      Treatment of Estrogen replacement
                        headache
 replacement therapy:   Reduce estrogen dose
 45% improve, 46%       Change estrogen type from conjugated
 worsen, and 9% are     estrogen (Premarin) to pure estrone
                        (Ogen)
 unchanged.
                        Convert from interrupted to
                        continuous dosing
                        Convert from oral to parenteral dosing
                        (Alora, Climara, Estraderm, or Vivelle-
                        Dot)
                        Add Androgens
Oral Contraceptive Use and
Migraine (1).
Migraines may occur for the first time following oral
 contraceptive use
OC’s effect on migraines is quite variable: migraines
 may increase, decrease, or stay the same
OC Use and Migraines: Risk of
Stroke (1).
Stroke in Young Women
  Annual occurrence of stroke in young women who take
   OCs is about 4 in 100,000 for women aged 25-34 and 11
   in 100,000 in women aged 35-44.
  For women who do not have migraine and do not take
   OCs: 1.3 in 100,000 in women aged 25-34 and 3.6 in
   100,000 for women aged 35-44.
Stroke and Migraine
  Increased risk of stroke in women with migraine
Approximate Risk of Stroke in
Young Women not on OC with and
without migraine (1).
Approximate incidence of ischemic stroke (strokes per 100,000 women per
year) in women with and without migraine who do not use oral
contraceptives.
                                                    Migraine
Age               Without Migraine   Without Aura       With Aura
25-34             1.3                4                  8
35-44             3.6                11                 22
OC Use and Migraines: Stroke and
Use of OCs (1).
Risk of stroke associated with OCs vary with different
 doses of estrogen.
Recent studies have not shown an increased risk of
 stroke in women who use low-estrogen-dose OCs.
OCs containing only progesterone do not increase the
 risk of stroke.
OC Use and Migrane: Use of Oral
Contraceptives in Migraneurs (1).
Most recent OC use and stroke studies reveal no
 increased risk of stroke in OC use in migraineurs.
Most women with migraine without aura and those
 with auras such as visual symptoms lasting less than
 one hour can use OCs.
Women with aura symptoms such as hemiparesis or
 dysphasia or prolonged focal neurological symptoms
 and signs lasting more than one hour should avoid
 low-dose-estrogen Ocs.
Progesterone-only OCs and many other contraceptive
 options may also be considered as a replacement.
Headaches during Pregnancy and
Postpartum (1).
About 90% of headaches during pregnancy and
 postpartum are BENIGN.
Frequency of migraines decreases and that of tension-
 type headaches does not change.
Life threatening causes of headache that can occur
 during this time: Preeclampsia and eclampsia,
 subarachnoid hemorrhage, intracerebral hemorrhage,
 and cerebral venous thrombosis.
Migraine during Pregnancy and
Postpartum (1).
Occurs in 1% and 10% of migraineurs during
 pregnancy, usually during the first trimester.
During pregnancy, preexisting migraine improves or
 disappears in about 60% or more, is unchanged in
 20% or less, and grows more frequent in 20% or less.
 Improvement often occurs in 2nd or 3rd trimester.
Migraine during Pregnancy and
Postpartum (1).
When improvement occurs during the first
 pregnancy, improvement also occurs during
 subsequent pregnancies in about 50%, whereas an
 increased frequency occurs in the other 50%.
Migraneurs do not have an increased risk of
 miscarriages, toxemia, congenital anomalies, or
 stillbirth.
Management (1).
Fortunately, migraines usually improve or disappear
 during pregnancy.
Nonmedication approaches: avoidance of triggers,
 ice, sleep, and biofeedback.
Symptomatic Medications: Acetaminophen
  FDA Class B drug (no evidence of risk in humans, but
   no controlled human studies)
  Caffeine in small doses of less than 300mg a day is Class
   B and safe.
  Codeine in reasonable amounts is probably safe
  Triptans should be AVOIDED during pregnancy.
Preventive Medications (1).
Valproic acid to be avoided (Class D)
Topiramate (Class C) should only by used if benefits
 outweigh risks.
Preventive of choice: Beta-blockers
Calcium channel blocker verapamil—safe during
 pregnancy
Antidepressants may be considered in some cases.
References
1. Evans, Randolph W. Headache in Women. Pages
   230-240. Handbook of Headache 2nd ed, 2005.
2. Goadsby, Peter. Update in Headache. Page 140.
   2008 AAN Timeline: Neurology Update II,2008.
3. Sabbatini, Dr. Renato M.E. Are There Differences
   Between the Brains of Males and Females? State
   University of Campinas 1997.
   <http://www.cerebromente.org.br/n11/mente/eisnte
   in/cerebro-homens.html>.
Dedicated to my family
for making everything worthwhile
READ not to contradict or confute
Nor to Believe and Take for Granted
but TO WEIGH AND CONSIDER


THANK YOU

Headache and migrane in women

  • 1.
    Prof. Dr. A.V.SRINIVASAN M.D., D.M., Ph.D (Neuro)DSC(HON), F.A.A.N., F.I.A.N, FORMER -Professor in Neurology and HEAD Institute of Neurology, MMC & GGH 17-06-2011
  • 2.
    Male Brain vs.Female Brain Different in external anatomical and primary and secondary sexual differences There are also differences in the way male and female brains process language, information, emotion, cognition, etc (3).
  • 3.
    Differences Male Brain Female Brain Better in Mathematical Better in human relations. calculations, etc. Higher than males in Higher than females in empathy, verbal skills, social independence, dominance, skills, and security seeking spatial and mathematical (3). skills, rank-related aggression, and other characteristics (3).
  • 4.
    Physiological Differences Brain regionin cortex discovered by scientists in Johns Hopkins University: inferior-parietal lobule (IPL). Significantly larger in men than in women. This area is bilateral and located just above the parietal cortex (above the level of the ears). Left IPL larger for men, while right IPL larger for women. Women have more grey matter volume than do men (3).
  • 5.
    Regions other thanthe Cortex the volume of a specific nucleus in the hypothalamus (third cell group of the interstitial nuclei of the anterior hypothalamus) is twice as large in heterosexual men than in women and homosexual men, thus prompting a heated debate whether there is a biological basis for homosexuality (3).
  • 6.
    Headaches Common medical Types: problem by any standard Migrane Represents most Tension common reason for Cluster referral for Neurologists (2).
  • 7.
    Migraine Migraine—disorder of sensorydysmodulation (2). Most common of the disabling primary headaches Represents 90% of headache complaints Pathophysiology: inherited problem (2). Thus far, 3 genes for familial hemiplegic migraine identified Each involve dysfuntion of ion channels.
  • 8.
    Headaches in Women Womenhave headaches more commonly than men. Prevalence of migraine: 18% of women and 6% of men. Estrogen levels are a key factor in increased prevalence of migraine in women (1).
  • 9.
    Evidence of theEffect of Estrogen levels on Migraines Migraine prevalence increases at menarche Estrogen withdrawal during menstruation is a common trigger for migraine Estrogen administration in oral contraceptives and hormone replacement therapies can also trigger migraines. Migraines decrease during the 2nd and 3rd trimesters of pregnancy when estrogen levels are high Migraines are common immediately postpartum, with the precipitous drop in estrogen levels Migraines generally improve with physiological menopause (1).
  • 10.
    Effects of Estrogenlevels (1). Fluctuations of estrogen levels can result in: Changes in prostaglandins and the uterus Prolactin release Opioid regulation Melatonin secretion Changes in neurotransmitters  I.e. Catecholamines, noradrenaline, serotonin, dopamine, and endorphins.
  • 11.
    Lifetime Prevalence ofHeadaches in Women and Men (1). Type Women Men Any Headache 99% 93% Migraine 25% 8% Tension 88% 69%
  • 12.
    Important Headache Issuesto be Covered (1). Menstrual Migraine Menopause and Migraine Oral Contraceptive Use in Migraineurs Headaches during Pregnancy and Postpartum
  • 13.
    Menstrual Migraine (1). Prevalencevaries from 4% to 73% Menstruation is trigger for about 60% of migraineurs. Symptoms of premenstrual syndrome include: depression, anxiety, crying spells, difficulty thinking, lethargy, backache, breast tenderness, swelling, and nausea. Both Migraine and tension-type headaches can be associated.
  • 14.
    Management of Menstrual Migraine(1). Symptomatic treatment same as for other migraines – NSAIDs (nonsteroidal antiinflammatory drugs) – ergotamine, dihydroergotamine, and triptans. Premenstrual preventive treatment can be helpful for women with frequent migraines or with menstrual migraines that are severe and prolonged.
  • 15.
    Management of Menstrual Migraine(1)> Effective Hormonal treatments Transdermal estradiol Bromocriptine 2.5mg, three times a day Danazol 200mg, two or three times a day Tamoxifen 5 to 15mg daily for days 7-14 of the luteal cycle. Hysterectomy is NOT RECOMMENDED for the management of menstrual migraine.
  • 16.
    Menopause and Migraines(1). 2/3rds of women with prior migraine improve with physiological menopause. Contrastingly, surgical menopause results in the worsening of migraine in 2/3rds of cases.
  • 17.
    Menopause and Migraines: EstrogenReplacement Therapy (1). Effect of hormone Treatment of Estrogen replacement headache replacement therapy: Reduce estrogen dose 45% improve, 46% Change estrogen type from conjugated worsen, and 9% are estrogen (Premarin) to pure estrone (Ogen) unchanged. Convert from interrupted to continuous dosing Convert from oral to parenteral dosing (Alora, Climara, Estraderm, or Vivelle- Dot) Add Androgens
  • 18.
    Oral Contraceptive Useand Migraine (1). Migraines may occur for the first time following oral contraceptive use OC’s effect on migraines is quite variable: migraines may increase, decrease, or stay the same
  • 19.
    OC Use andMigraines: Risk of Stroke (1). Stroke in Young Women Annual occurrence of stroke in young women who take OCs is about 4 in 100,000 for women aged 25-34 and 11 in 100,000 in women aged 35-44. For women who do not have migraine and do not take OCs: 1.3 in 100,000 in women aged 25-34 and 3.6 in 100,000 for women aged 35-44. Stroke and Migraine Increased risk of stroke in women with migraine
  • 20.
    Approximate Risk ofStroke in Young Women not on OC with and without migraine (1). Approximate incidence of ischemic stroke (strokes per 100,000 women per year) in women with and without migraine who do not use oral contraceptives. Migraine Age Without Migraine Without Aura With Aura 25-34 1.3 4 8 35-44 3.6 11 22
  • 21.
    OC Use andMigraines: Stroke and Use of OCs (1). Risk of stroke associated with OCs vary with different doses of estrogen. Recent studies have not shown an increased risk of stroke in women who use low-estrogen-dose OCs. OCs containing only progesterone do not increase the risk of stroke.
  • 22.
    OC Use andMigrane: Use of Oral Contraceptives in Migraneurs (1). Most recent OC use and stroke studies reveal no increased risk of stroke in OC use in migraineurs. Most women with migraine without aura and those with auras such as visual symptoms lasting less than one hour can use OCs. Women with aura symptoms such as hemiparesis or dysphasia or prolonged focal neurological symptoms and signs lasting more than one hour should avoid low-dose-estrogen Ocs. Progesterone-only OCs and many other contraceptive options may also be considered as a replacement.
  • 23.
    Headaches during Pregnancyand Postpartum (1). About 90% of headaches during pregnancy and postpartum are BENIGN. Frequency of migraines decreases and that of tension- type headaches does not change. Life threatening causes of headache that can occur during this time: Preeclampsia and eclampsia, subarachnoid hemorrhage, intracerebral hemorrhage, and cerebral venous thrombosis.
  • 24.
    Migraine during Pregnancyand Postpartum (1). Occurs in 1% and 10% of migraineurs during pregnancy, usually during the first trimester. During pregnancy, preexisting migraine improves or disappears in about 60% or more, is unchanged in 20% or less, and grows more frequent in 20% or less. Improvement often occurs in 2nd or 3rd trimester.
  • 25.
    Migraine during Pregnancyand Postpartum (1). When improvement occurs during the first pregnancy, improvement also occurs during subsequent pregnancies in about 50%, whereas an increased frequency occurs in the other 50%. Migraneurs do not have an increased risk of miscarriages, toxemia, congenital anomalies, or stillbirth.
  • 26.
    Management (1). Fortunately, migrainesusually improve or disappear during pregnancy. Nonmedication approaches: avoidance of triggers, ice, sleep, and biofeedback. Symptomatic Medications: Acetaminophen FDA Class B drug (no evidence of risk in humans, but no controlled human studies) Caffeine in small doses of less than 300mg a day is Class B and safe. Codeine in reasonable amounts is probably safe Triptans should be AVOIDED during pregnancy.
  • 27.
    Preventive Medications (1). Valproicacid to be avoided (Class D) Topiramate (Class C) should only by used if benefits outweigh risks. Preventive of choice: Beta-blockers Calcium channel blocker verapamil—safe during pregnancy Antidepressants may be considered in some cases.
  • 28.
    References 1. Evans, RandolphW. Headache in Women. Pages 230-240. Handbook of Headache 2nd ed, 2005. 2. Goadsby, Peter. Update in Headache. Page 140. 2008 AAN Timeline: Neurology Update II,2008. 3. Sabbatini, Dr. Renato M.E. Are There Differences Between the Brains of Males and Females? State University of Campinas 1997. <http://www.cerebromente.org.br/n11/mente/eisnte in/cerebro-homens.html>.
  • 29.
    Dedicated to myfamily for making everything worthwhile
  • 30.
    READ not tocontradict or confute Nor to Believe and Take for Granted but TO WEIGH AND CONSIDER THANK YOU